Thermo Fisher Scientific (NYSE:TMO) Shares Gap Up After Better-Than-Expected Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) gapped up before the market opened on Thursday following a better than expected earnings announcement. The stock had previously closed at $526.46, but opened at $573.68. Thermo Fisher Scientific shares last traded at $573.9670, with a volume of 1,505,888 shares.

The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business’s revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Thermo Fisher Scientific News Summary

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher reported Q2 adjusted EPS of $6.03, ahead of the $5.71 consensus, with revenue of $11.99 billion also topping estimates. Why Is Thermo Fisher (TMO) Stock Rocketing Higher Today
• Positive Sentiment: Management raised full-year FY2026 guidance, with EPS and revenue outlooks both coming in above Wall Street expectations, signaling confidence in continued demand and execution. Thermo Fisher Scientific Inc (TMO) Q2 2026 Earnings Call Highlights
• Positive Sentiment: Improving customer activity across end markets and continued organic growth helped ease investor concerns about a prolonged slowdown in medical research and tools demand. The ‘Standout Performance’ That Could Save Thermo Fisher, Danaher And Others
• Neutral Sentiment: Separately, Thermo Fisher was selected by ImmuPharma to help manufacture its Kapiglucagon diabetes candidate, a modest business development update that supports the company’s CDMO pipeline but is not likely to move shares on its own. ImmuPharma picks Thermo Fisher to manufacture diabetes drug candidate

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent research reports. Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Royal Bank Of Canada set a $490.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research report on Thursday, May 14th. Robert W. Baird dropped their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Piper Sandler started coverage on shares of Thermo Fisher Scientific in a research note on Thursday, June 11th. They set a “neutral” rating and a $510.00 target price for the company. Finally, HSBC lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their price target for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $606.45.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Merit Financial Group LLC raised its holdings in Thermo Fisher Scientific by 47.9% during the second quarter. Merit Financial Group LLC now owns 21,997 shares of the medical research company’s stock worth $11,028,000 after purchasing an additional 7,125 shares in the last quarter. Diversified Trust Co. boosted its holdings in Thermo Fisher Scientific by 71.1% in the 2nd quarter. Diversified Trust Co. now owns 17,214 shares of the medical research company’s stock valued at $8,630,000 after purchasing an additional 7,155 shares in the last quarter. Cary Street Partners Financial LLC increased its position in Thermo Fisher Scientific by 3.3% during the 2nd quarter. Cary Street Partners Financial LLC now owns 33,339 shares of the medical research company’s stock worth $16,715,000 after purchasing an additional 1,056 shares during the period. Liberty Capital Management Inc. purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $8,524,000. Finally, Baker Tilly Wealth Management LLC boosted its stake in shares of Thermo Fisher Scientific by 43.3% in the second quarter. Baker Tilly Wealth Management LLC now owns 1,456 shares of the medical research company’s stock valued at $730,000 after buying an additional 440 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

The stock has a fifty day moving average of $491.42 and a two-hundred day moving average of $513.08. The stock has a market cap of $213.10 billion, a price-to-earnings ratio of 31.52, a price-to-earnings-growth ratio of 2.33 and a beta of 0.87. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.